Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression

Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression

The v-raf murine sarcoma viral oncogenic homolog B1 (BRAF) V600E is a rare mutation that functions as an oncogenic driver in patients with non-small cell lung cancer (NSCLC) leading to the overactivation of the RAS-RAF-MEK-ERK (MAPK) pathway and the subsequent uncontrolled cell proliferation. Unders...

Full description

Bibliographic Details
Main Authors:	Huimin Zhang, Xiaofeng Cong, Jiaxin Yin, Chen Chen, Ziling Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Oncology
Subjects:	dabrafenib trametinib BRAF V600E mutation BRCA2 germline mutation lung adenocarcinoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1387388/full

Similar Items

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
by: Morena Fasano, et al.
Published: (2022-01-01)

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
by: Sandip Ganguly, et al.
Published: (2021-09-01)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
by: David Balakirouchenane, et al.
Published: (2020-04-01)

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study
by: Michele Del Vecchio, et al.
Published: (2023-03-01)

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review
by: Ruoxin Fang, et al.
Published: (2023-07-01)

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review
by: Gudrun Piringer, et al.
Published: (2023-05-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
by: Walid Shalata, et al.
Published: (2023-02-01)

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyResearch in context
by: Xue Bai, et al.
Published: (2023-11-01)

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
by: Baptiste Le Calvez, et al.
Published: (2020-07-01)

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
by: Bárbara Lima, et al.
Published: (2022-04-01)

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
by: Carola Berking, et al.
Published: (2023-09-01)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
by: Nora Isberner, et al.
Published: (2022-09-01)

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
by: Orion Valet, et al.
Published: (2021-06-01)

Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
by: Po-Lan Su, MD, et al.
Published: (2021-08-01)

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
by: Yuta Adachi, et al.
Published: (2020-02-01)

Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report
by: Ji Eun Shin, et al.
Published: (2022-11-01)

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
by: Weart TC, et al.
Published: (2018-04-01)

Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
by: Quaglino P, et al.
Published: (2023-11-01)

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
by: Wei Wang, et al.
Published: (2021-09-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
by: Ken Saijo, et al.
Published: (2022-08-01)

Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report
by: Li D, et al.
Published: (2022-11-01)

Exceptionally long‐lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD‐L1: A case report
by: Takako Inoue, et al.
Published: (2024-04-01)

Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E‐positive non–small cell lung cancer: A case report
by: Yoshihiko Taniguchi, et al.
Published: (2023-05-01)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with <em>BRAF</em> V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
by: Jean-Bernard Auliac, et al.
Published: (2020-12-01)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
by: Vincenzo Di Nunno, et al.
Published: (2023-01-01)

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation
by: Jingjing Qu, et al.
Published: (2022-06-01)

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
by: Victoria G. Atkinson, et al.
Published: (2021-05-01)

Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report
by: Yang Yang, et al.
Published: (2021-12-01)

Successful dabrafenib and trametinib combination therapy in a patient with recurrent BRAF V600E‐mutant non‐small‐cell lung cancer and coexisting radiation pneumonitis
by: Eriko Nakamura, et al.
Published: (2024-01-01)

Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report
by: Fang R, et al.
Published: (2024-01-01)

Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in <i>BRAF</i> and p.R461* in <i>NF1</i> Genes—A Case Report with Literature Review
by: Anna Grenda, et al.
Published: (2023-01-01)

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements
by: Alia Thawer, et al.
Published: (2021-09-01)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
by: Karisa C. Schreck, et al.
Published: (2019-08-01)

A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma
by: Maria Chiara Tronconi, et al.
Published: (2022-05-01)

Non-small-cell lung cancer: how to manage BRAF-mutated disease
by: Giorgia Guaitoli, et al.
Published: (2023-05-01)

Ocular toxicity due to Trametinib and Dabrafenib
by: Stephanie Sarny, et al.
Published: (2017-08-01)

Dabrafenib plus trametinib versus nivolumab for advanced melanoma
by: Daniela Lahoz, et al.
Published: (2023-02-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
by: Simeng Zhang, et al.
Published: (2023-01-01)

Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report
by: Ziyao Wang, et al.
Published: (2022-01-01)

Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib
by: Hiroshi Kato, et al.
Published: (2023-09-01)